The need for high safer and more potent therapies for cancer patients led Himalaya to the Conditionally Active Biologics (CAB) technology. CAB antibodies are innovative, differentiated therapeutics. They are selective and bind reversibly only to targets on tumor cells, and not on normal cells, thereby widening the therapeutic window. In non-human primate and patient studies to date, CAB antibodies have demonstrated high safety with higher potency.
As cancer therapies, CAB antibodies are active in the microenvironment associated with cancer cells, and inactive against normal cells, which lack this micro environment. CAB antibodies can reduce or eliminate potential on-target, off-tumor toxicity, offering improved safety and efficacy, while also enabling combination therapies which have suffered from significant safety challenges. CAB antibodies are a solution to toxicity challenges associated with cancer therapies, allowing for the potential of more effective treatments.
Himalaya is advancing a pipeline of multiple CAB antibodies, licensed exclusively from BioAtla.
This pipeline includes two US P1/2 clinical stage (CAB-AXL-ADC and CAB-ROR2-ADC) and three preclinical stage CAB antibody cancer therapeutics in greater China. In addition, the company has rights to two preclinical antibodies (one CAB-bispecific and one non-CAB antibody) worldwide.
In 2019, we achieved our first exclusive out-license of one of our preclinical stage drugs, CAB-CTLA4, with Beigene and BioAtla for the greater China territory. We are eligible to receive development and commercial milestones, as well as royalties from product sales. Our CAB-CTLA4 has the potential to enhance the efficacy of one of the few validated combination checkpoint inhibitor therapies, together with Beigene’s leading PD-1 drug candidate, as well as for improved monotherapy treatment in selected cancers.
Drug quality and safety for patients are of utmost importance to Himalaya. We employ precision medicine practices to tailor drugs to individual patients.
Clinical trials are human research studies are designed to evaluate if an investigational medicine is safe and effective for patients. Learn more about ongoing clinical trials for Himalaya’s CAB antibodies (through BioAtla) here. In coordination with BioAtla, Himalaya is leading the clinical development in its territories for its drugs.
For more information, contact us here**